Two publications have just been released, on Hemeo’s research: “Assessing the risk of DIC development in sepsis and SIRS” and “Real-world data on the effect of anticoagulants to prevent or treat DIC.” These publications are now available on our website, on the Resources page.
We are proud to be part of this well known event and get the opportunity to share our story with a broader audience. We are gaining momentum across different communities, investors, clinicians, researchers.
Europe is a great ecosystem for innovation in healthtech, and in medtech in particular, with active regional innovation hubs, companies used to cooperate with stakeholders, excellent universities and research institutes and public and private investors. The Reflection Paper on Innovation in Medtech, released by MedTech Europe in Nov 2020 has highlighted the value of bridging the gap between innovative start-ups and global companies More can be done in strengthening their cooperation. Three success stories will be presented in tandem talks between corporates and start-ups to illustrate the ups and downs of such cooperation.
Next to the presentation of the Hemeo case by CEO Remi Corlin, two other speakers will present their case: Mark Bloemendaal, CEO of Angiogenesis Analytics, and Ilker Soydan, CEO of EchoGuide. The session at the MedTech Forum will be moderated by Nina Rijnders, responsible for Corporate Partnerships at NLC, The European Healthech Venture Builder.
more info: https://www.themedtechforum.eu/
We are delighted to announce that Hemeo received seed funding from the Momentum fund. This 2.2M€ fund is designed to provide private investors the opportunity to invest in startups at an early stage while spreading the risk across a portfolio of ventures.
With this funding, Hemeo is able to initiate work with clinicians and hospitals to design our very first application. We are enthused by the strong support received from the clinician community and the ongoing collaboration with 5 leading academic hospitals.